ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment can ...
ATTR phenotypes vary by genotype as well as by gene penetrance, age, and geographic location. A new analysis examined data from untreated, symptomatic patients who had 1 of 4 variants: F64L, I68L, ...
Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. While cardiomyopathy is a ...
BOSTON - Researchers at Boston Medical Center (BMC) and Boston University School of Medicine (BUSM), in collaboration with Columbia University Irving Medical Center (CUIMC), are leading a national, ...
- Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 - BOSTON & SAN FRANCISCO--(BUSINESS ...
AMSTERDAM, the Netherlands—Top-line results of ATTRibute-CM were already known, but a new Hot Line presentation at the European Society of Cardiology (ESC) Congress 2023 delivered more information ...
The prognosis for people with ATTR amyloidosis depends on a range of factors, including the type they have, which organs are impacted, and the kind of treatment they’ve received. In amyloidosis, ...
Pacing device implants (PDIs) or implantable cardioverter-defibrillators (ICD) may be placed to treat or prevent the consequences of amyloid deposits (heart failure and conduction disturbances) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback